-
1
-
-
14944385553
-
Global cancer statistics, 2002
-
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
-
(2005)
CA Cancer J Clin
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
2
-
-
84872659173
-
Patient-derived breast tumor xenografts facilitating personalized cancer therapy
-
Landis MD, Lehmann BD, Pietenpol JA et al. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res 2013; 15: 201.
-
(2013)
Breast Cancer Res
, vol.15
, pp. 201
-
-
Landis, M.D.1
Lehmann, B.D.2
Pietenpol, J.A.3
-
3
-
-
84929074678
-
-
(10 December 2014, date last accessed)
-
Product monograph [database on the Internet] 2010. http://hemonc.org/docs/packageinsert/trabectedin.pdf (10 December 2014, date last accessed).
-
(2010)
Product monograph [database on the Internet]
-
-
-
4
-
-
20144388299
-
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production
-
Allavena P, Signorelli M, Chieppa M et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005; 65: 2964-2971.
-
(2005)
Cancer Res
, vol.65
, pp. 2964-2971
-
-
Allavena, P.1
Signorelli, M.2
Chieppa, M.3
-
5
-
-
84873597334
-
Role of macrophage targeting in the antitumor activity of trabectedin
-
Germano G, Frapolli R, Belgiovine C et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013; 23: 249-262.
-
(2013)
Cancer Cell
, vol.23
, pp. 249-262
-
-
Germano, G.1
Frapolli, R.2
Belgiovine, C.3
-
6
-
-
77955491837
-
Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
-
Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28: 3107-3114.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3107-3114
-
-
Monk, B.J.1
Herzog, T.J.2
Kaye, S.B.3
-
7
-
-
84867525162
-
Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer
-
Monk BJ, Dalton H, Benjamin I et al. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer. Curr Pharm Des 2012; 18(25): 3754-3769.
-
(2012)
Curr Pharm Des
, vol.18
, Issue.25
, pp. 3754-3769
-
-
Monk, B.J.1
Dalton, H.2
Benjamin, I.3
-
8
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
9
-
-
84929075267
-
Phase II prospective study on trabectedin (T) in BRCA-mutated and BRCAness phenotype advanced ovarian cancer (AOC) patients (pts): The MITO 15 trial
-
Lorusso D FG, Pignata S, Sorio R et al. Phase II prospective study on trabectedin (T) in BRCA-mutated and BRCAness phenotype advanced ovarian cancer (AOC) patients (pts): The MITO 15 trial. J Clin Oncol 2014; 32: 5s (suppl; abstr 5530).
-
(2014)
J Clin Oncol
, vol.32
, pp. 5s
-
-
Lorusso, D.F.G.1
Pignata, S.2
Sorio, R.3
-
10
-
-
0033558282
-
Survival in familial, brca1-associated, and brca2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) familial ovarian cancer study group
-
Pharoah PD, Easton DF, Stockton DL et al. Survival in familial, brca1-associated, and brca2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) familial ovarian cancer study group. Cancer Res 1999; 59: 868-871.
-
(1999)
Cancer Res
, vol.59
, pp. 868-871
-
-
Pharoah, P.D.1
Easton, D.F.2
Stockton, D.L.3
-
11
-
-
33847167062
-
Improved survival in brca2 carriers with ovarian cancer
-
Pal T, Permuth-Wey J, Kapoor R et al. Improved survival in brca2 carriers with ovarian cancer. Fam Cancer 2007; 6: 113-119.
-
(2007)
Fam Cancer
, vol.6
, pp. 113-119
-
-
Pal, T.1
Permuth-Wey, J.2
Kapoor, R.3
-
12
-
-
57149093237
-
'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with brca1 and brca2 mutations
-
Tan DS, Rothermundt C, Thomas K et al. 'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with brca1 and brca2 mutations. J Clin Oncol 2008; 26: 5530-5536.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5530-5536
-
-
Tan, D.S.1
Rothermundt, C.2
Thomas, K.3
-
13
-
-
84876415689
-
Brca1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a gynecologic oncology group study
-
Lesnock JL, Darcy KM, Tian C et al. Brca1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a gynecologic oncology group study. Br J Cancer 2013; 108: 1231-1237.
-
(2013)
Br J Cancer
, vol.108
, pp. 1231-1237
-
-
Lesnock, J.L.1
Darcy, K.M.2
Tian, C.3
-
14
-
-
84859523588
-
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
-
Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392.
-
(2012)
N Engl J Med
, vol.366
, pp. 1382-1392
-
-
Ledermann, J.1
Harter, P.2
Gourley, C.3
-
15
-
-
84856158117
-
Association between brca1 and brca2 mutations and survival in women with invasive epithelial ovarian cancer
-
Bolton KL, Chenevix-Trench G, Goh C et al. Association between brca1 and brca2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012; 307: 382-390.
-
(2012)
JAMA
, vol.307
, pp. 382-390
-
-
Bolton, K.L.1
Chenevix-Trench, G.2
Goh, C.3
-
16
-
-
84872517041
-
Long-term ovarian cancer survival associated with mutation in brca1 or brca2
-
McLaughlin JR, Rosen B, Moody J et al. Long-term ovarian cancer survival associated with mutation in brca1 or brca2. J Natl Cancer Inst 2013; 105: 141-148.
-
(2013)
J Natl Cancer Inst
, vol.105
, pp. 141-148
-
-
McLaughlin, J.R.1
Rosen, B.2
Moody, J.3
-
17
-
-
41549100818
-
DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (et-743)
-
Schoffski PCP, Taron M et al. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (et-743). J Clin Oncol 2006; 24: 525s (suppl; abstr 9522).
-
(2006)
J Clin Oncol
, vol.24
, pp. 525s
-
-
Schoffski, P.C.P.1
Taron, M.2
|